Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIVEC: Induction PD-1 blockade (nivolumab) in resectable mismatch repair deficient endometrial cancer
KCT0008286Phase 2Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of nivolumab in Sarcoma of the urogenital tract, sponsored by Ono Pharmaceutical. Started Oct 2023; status: recruiting.
02
Drugs
03
Conditions
Sarcoma of the urogenital tract
Beyond the preview
Go deeper on KCT0008286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008286.